HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

LEADS BIOLABS-B

59.450

-0.050-0.08%

Volume:341.70K

Turnover:20.15M

Market Cap:11.83B

PE:-29.61

High:60.900

Open:59.000

Low:57.200

Close:59.500

52wk High:83.600

52wk Low:51.600

Shares:199.00M

HK Float Shares:153.00M

Volume Ratio:1.55

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.008

ROE:--

ROA:--

PB:102.99

PE(LYR):-29.61

PS:- -

Loading ...

Overview Company News Filings

Nanjing Leads Biolabs - Will Receive Upfront and Potential Near-Term Milestone Payments up to $38 Mln, up to $1 Bln in Potential Clinical Development

THOMSON REUTERS

LEADS BIOLABS-B (09887): Research Results of Two Innovative Drugs to Be Presented at 67th ASH Annual Meeting

Nanjing Leads Biolabs to Present Research Results of Two Innovative Drugs at 67th ASH Annual Meeting

Exploring Nanjing Leads Biolabs (SEHK:9887) Valuation: Does the Market See Hidden Potential?

Simply Wall St.

Nanjing Leads Biolabs' IND Application Gains US FDA Approval for Autoimmune Therapy

MT Newswires Live

LEADS BIOLABS-B (09887): LBL-047 Receives IND Approval from US FDA

Nanjing Leads Biolabs Co Ltd - Lbl-047 Receives Ind Approval From U.S. FDA

THOMSON REUTERS

Hong Kong Stock Movement | LEADS BIOLABS-B (09887) Surges Over 10% in Morning Trading as Core Product LBL-024 Completes First Patient Dosing in Melanoma Trial

Hong Kong Stock Movement | LEADS BIOLABS-B (09887) Surges Over 5% in Afternoon Session Following First Patient Enrollment in LBL-024 Melanoma Phase Ib/II Clinical Trial

Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1B/Ii Trial of Opamtistomig

THOMSON REUTERS

LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment

Nanjing Leads Biolabs Co. Ltd. Announces First Patient Dosed in Phase Ib/II Trial for Advanced Melanoma Treatment

Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation as Investor Interest Grows Without Clear Catalyst

Simply Wall St.

Nanjing Leads Biolabs Narrows H1 Loss; Shares Gain 2%

MT Newswires Live

LEADS BIOLABS-B (09887) Reports Interim Results with Net Loss of Approximately RMB 166 Million, Down 7.8% Year-on-Year

BRIEF-Nanjing Leads Biolabs Posts HY Loss Attributable Of RMB166.4 MLN

Nanjing Leads Biolabs - Hy Loss Attributable RMB166.4 Mln

THOMSON REUTERS

Nanjing Leads Biolabs Doses First Patient in Phase 2 Study of Cancer Drug

MT Newswires Live

Clinical Development Accelerates! LEADS BIOLABS-B (09887) TCE Bispecific Antibody Shows CAR-T Comparable Efficacy in Phase I, First Patient Successfully Dosed in Phase II

Acceleration in Clinical Development! Leads Biolabs' Lbl-034 Dosed First Patient in Phase Ⅱ Trial

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/09887/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":59.45,"timestamp":1763096930286,"preClose":59.5,"halted":0,"volume":341700,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"Trading","change":-0.05,"latestTime":"11-14 13:09:21","open":59,"high":60.9,"low":57.2,"amount":20147085,"amplitude":0.062185,"askPrice":59.55,"askSize":400,"bidPrice":59.45,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1763107800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":59.5,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":1.554726,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.554726,"shares":199000000,"dividePrice":0,"high":60.9,"amplitude":0.062185,"preClose":59.5,"low":57.2,"week52Low":51.6,"pbRate":"102.99","week52High":83.6,"institutionHeld":0,"latestPrice":59.45,"committee":0.2,"eps":-2.008042,"divideRate":0,"volume":341700,"delay":0,"ttmEps":-1.858667,"open":59,"prevYearClose":35,"prevWeekClose":58.45,"prevMonthClose":53.7,"prevQuarterClose":69.95,"fiveDayClose":58.45,"twentyDayClose":66.25,"sixtyDayClose":73.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-11-12","current":-32.012189,"percent":0.933333,"low":-50.052922,"twenty":-44.115151,"median":-41.529709,"eighty":-39.201212,"high":-34.030535,"avg":-41.427746,"sd":3.156628,"marketCap":11416389320},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-12","current":-36.397343,"twenty":-44.115151,"median":-41.529709,"eighty":-39.201212,"marketCap":11416389320}],"updateTime":1763059415624},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575499437","title":"Nanjing Leads Biolabs - Will Receive Upfront and Potential Near-Term Milestone Payments up to $38 Mln, up to $1 Bln in Potential Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2575499437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575499437?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:49","pubTimestamp":1760618947,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX2MO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1182886188","title":"LEADS BIOLABS-B (09887): Research Results of Two Innovative Drugs to Be Presented at 67th ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1182886188","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182886188?lang=en_us&edition=fundamental","pubTime":"2025-10-09 06:30","pubTimestamp":1759962616,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the American Society of Hematology (ASH) has released the abstract review results for its 67th Annual Meeting. The company's two innovative drugs have achieved...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4109","09887","BK1574","159992","06978","BK1161","ASH"],"gpt_icon":0},{"id":"2574704903","title":"Nanjing Leads Biolabs to Present Research Results of Two Innovative Drugs at 67th ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2574704903","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574704903?lang=en_us&edition=fundamental","pubTime":"2025-10-09 06:23","pubTimestamp":1759962201,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. has announced that research results for two innovative drugs will be presented at the 67th American Society of Hematology  Annual Meeting. According to the company, five research abstracts have been accepted, including one oral presentation, three poster presentations, and one online publication. The results are scheduled to be presented at the upcoming meeting. The company highlighted that this inclusion reflects international recognition of its scientific and innovative capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief on October 09, 2025, and is solely responsible for the information contained ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL3XbhPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2569737336","title":"Exploring Nanjing Leads Biolabs (SEHK:9887) Valuation: Does the Market See Hidden Potential?","url":"https://stock-news.laohu8.com/highlight/detail?id=2569737336","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569737336?lang=en_us&edition=fundamental","pubTime":"2025-09-22 21:48","pubTimestamp":1758548880,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (SEHK:9887) is catching some investor attention, and for good reason. Even without a headline event to point to, movements in its stock can make you wonder whether the market is quietly repositioning around its future prospects. Every shift, big or small, carries hints about what investors anticipate for this innovative biotech player.\nIf you zoom out, the story over the past year for Nanjing Leads Biolabs has been one of cautious stability. The stock has edged up just...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/exploring-nanjing-leads-biolabs-sehk9887-valuation-does-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/exploring-nanjing-leads-biolabs-sehk9887-valuation-does-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2569208537","title":"Nanjing Leads Biolabs' IND Application Gains US FDA Approval for Autoimmune Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2569208537","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569208537?lang=en_us&edition=fundamental","pubTime":"2025-09-22 12:37","pubTimestamp":1758515822,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  said the US Food and Drug Administration has cleared its investigational new drug application for LBL-047, a bispecific fusion protein targeting BDCA2 and TACI, according to a Monday Hong Kong bourse filing.The company said LBL-047 holds potential for treating autoimmune diseases, including systemic lupus erythematosus, dermatomyositis, IgA nephropathy, and Sjgren's syndrome.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1189947365","title":"LEADS BIOLABS-B (09887): LBL-047 Receives IND Approval from US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1189947365","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189947365?lang=en_us&edition=fundamental","pubTime":"2025-09-22 12:16","pubTimestamp":1758514578,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its proprietary drug LBL-047 on September 19, 2025....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2569627014","title":"Nanjing Leads Biolabs Co Ltd - Lbl-047 Receives Ind Approval From U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2569627014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569627014?lang=en_us&edition=fundamental","pubTime":"2025-09-22 12:01","pubTimestamp":1758513670,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nFWN3V70KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1197206028","title":"Hong Kong Stock Movement | LEADS BIOLABS-B (09887) Surges Over 10% in Morning Trading as Core Product LBL-024 Completes First Patient Dosing in Melanoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1197206028","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197206028?lang=en_us&edition=fundamental","pubTime":"2025-09-16 10:30","pubTimestamp":1757989828,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) jumped more than 10% during morning trading session. As of press time, the stock was up 8.04% to HK$69.85 with a turnover of HK$76.91 million. On the news front, LEADS BIOLABS...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","BK1161","BK4614","07226","YANG","09887"],"gpt_icon":1},{"id":"1145650234","title":"Hong Kong Stock Movement | LEADS BIOLABS-B (09887) Surges Over 5% in Afternoon Session Following First Patient Enrollment in LBL-024 Melanoma Phase Ib/II Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1145650234","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145650234?lang=en_us&edition=fundamental","pubTime":"2025-09-12 14:20","pubTimestamp":1757658027,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) experienced significant gains in afternoon trading, climbing over 5%. As of press time, the stock was up 4.84% to HK$65, with trading volume reaching HK$22.107 million. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2566947901","title":"Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1B/Ii Trial of Opamtistomig","url":"https://stock-news.laohu8.com/highlight/detail?id=2566947901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566947901?lang=en_us&edition=fundamental","pubTime":"2025-09-12 12:35","pubTimestamp":1757651739,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nTUA2W8187:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1188794473","title":"LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1188794473","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188794473?lang=en_us&edition=fundamental","pubTime":"2025-09-12 12:24","pubTimestamp":1757651064,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2566947569","title":"Nanjing Leads Biolabs Co. Ltd. Announces First Patient Dosed in Phase Ib/II Trial for Advanced Melanoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2566947569","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566947569?lang=en_us&edition=fundamental","pubTime":"2025-09-12 12:21","pubTimestamp":1757650888,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. has announced the initiation of a Phase Ib/II clinical trial evaluating the drug Opamtistomig , a PD-L1/4-1BB bispecific antibody, as a treatment for advanced melanoma. This trial will assess the drug's efficacy and safety both as a monotherapy and in combination with other agents for first-line treatment. The study, identified as NCT07099430, is being conducted across multiple centers in China and is led by Professor Chen Yu of Fujian Cancer Hospital. The company has successfully dosed the first patient, marking a significant step in the trial process. Results from this study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL5Wh3pP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2566823915","title":"Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation as Investor Interest Grows Without Clear Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2566823915","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566823915?lang=en_us&edition=fundamental","pubTime":"2025-09-11 22:24","pubTimestamp":1757600678,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (SEHK:9887) is catching the eye of investors this week, and while there hasn’t been a specific event driving the latest action, that in itself can be a signal worth watching. Sometimes investor attention turns to stocks that have posted significant moves or simply piqued market curiosity, leading many to ask what the story is and where real value might be hiding. In these situations, it is important to sift through the chatter and focus on the company’s fundamentals and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-as-invest","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-as-invest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2564818851","title":"Nanjing Leads Biolabs Narrows H1 Loss; Shares Gain 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564818851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564818851?lang=en_us&edition=fundamental","pubTime":"2025-09-01 16:56","pubTimestamp":1756717019,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  posted a loss attributable to owners of 166.4 million yuan for the first half of 2025, compared with a 180.4 million yuan loss a year earlier, according to an Aug. 29 Hong Kong bourse filing.Shares of the clinical-stage biotech were up nearly 2% in Monday afternoon trade.Loss per share was 1.06 yuan, compared with 1.22 yuan in the same period last year.It reported no nil revenue for the reporting period.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"1107800699","title":"LEADS BIOLABS-B (09887) Reports Interim Results with Net Loss of Approximately RMB 166 Million, Down 7.8% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1107800699","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107800699?lang=en_us&edition=fundamental","pubTime":"2025-08-29 22:06","pubTimestamp":1756476375,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced its interim results for 2025, with research and development costs of approximately RMB 132 million, representing a 56.9% year-on-year increase. The company recorded...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2563213960","title":"BRIEF-Nanjing Leads Biolabs Posts HY Loss Attributable Of RMB166.4 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2563213960","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563213960?lang=en_us&edition=fundamental","pubTime":"2025-08-29 21:52","pubTimestamp":1756475532,"startTime":"0","endTime":"0","summary":"BRIEF-Nanjing Leads Biolabs Posts HY Loss Attributable Of RMB166.4 MLNAug 29 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK:HY LOSS ATTRIBUTABLE RMB166.4 MILLIONFurther company coverage: 9887.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2563260900","title":"Nanjing Leads Biolabs - Hy Loss Attributable RMB166.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2563260900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563260900?lang=en_us&edition=fundamental","pubTime":"2025-08-29 21:21","pubTimestamp":1756473700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2562731249","title":"Nanjing Leads Biolabs Doses First Patient in Phase 2 Study of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2562731249","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562731249?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:08","pubTimestamp":1756123683,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (HKG:9887) dosed the first patient in a phase 2 trial of LBL-034 following strong phase I data, a Monday filing with the Hong Kong bourse said.The study aims to evaluate the effi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"1194708533","title":"Clinical Development Accelerates! LEADS BIOLABS-B (09887) TCE Bispecific Antibody Shows CAR-T Comparable Efficacy in Phase I, First Patient Successfully Dosed in Phase II","url":"https://stock-news.laohu8.com/highlight/detail?id=1194708533","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194708533?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:14","pubTimestamp":1756120487,"startTime":"0","endTime":"0","summary":"On August 25, LEADS BIOLABS-B (09887) announced that the company's independently developed GPRC5D/CD3 bispecific antibody has successfully completed enrollment of the first patient in its Phase II...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK1161","BK4022","CAR","09887"],"gpt_icon":0},{"id":"2562488202","title":"Acceleration in Clinical Development! Leads Biolabs' Lbl-034 Dosed First Patient in Phase Ⅱ Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2562488202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562488202?lang=en_us&edition=fundamental","pubTime":"2025-08-25 18:19","pubTimestamp":1756117179,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nTUABQ2XM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}